RHJA
CRNX

Rice Hall James & Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Rice Hall James & Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35M Buy
196,318
+617
+0.3% +$22.9K 0.36% 76
2026
Q1 		$7.11M Buy
195,701
+23,871
+14% +$1.07M 0.4% 67
2025
Q4 		$8M Sell
171,830
-2,247
-1% -$100K 0.44% 60
2025
Q3 		$7.25M Buy
+174,077
New +$5.57M 0.4% 67

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rice Hall James & Associates's CRNX Position: Q2 2026 in Review

Rice Hall James & Associates increased its Crinetics Pharmaceuticals (CRNX) stake by 0.32% in Q2 2026, buying an estimated $22.9K and bringing the position to 196,318 shares worth $7.35M. The position accounts for 0.36% of the portfolio, ranked #76.

Rice Hall James & Associates first reported a position in CRNX in Q3 2025 and has held it in 4 quarters since. The position peaked at $8M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Rice Hall James & Associates held 196,318 shares of Crinetics Pharmaceuticals worth $7.35M as of Q2 2026.
  • Rice Hall James & Associates bought 617 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $22.9K.
  • Crinetics Pharmaceuticals made up 0.36% of Rice Hall James & Associates's portfolio in Q2 2026, its #76 holding.
  • Rice Hall James & Associates first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Rice Hall James & Associates's Crinetics Pharmaceuticals position peaked at $8M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.